Filing Flows › Elite Pharmaceuticals (ELTP) › Q4 FY25
Elite Pharmaceuticals (ELTP) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jun 30, 2025
Elite Pharmaceuticals (ELTP) reported revenue of $32.0M for the fourth quarter fiscal 2025 (Q4 FY25), +78% from a year earlier and +123% from the quarter before. Operating margin was 34.9%, net earnings $17.0M (53.1% of revenue).
Elite Pharmaceuticals, Q4 FY25: revenue $32.0M (+78% year over year), operating margin 34.9%, net earnings $17.0M, operating cash flow $3.9M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.0M | +123% | +78% |
| Gross profit | $17.3M | +183% | +113% |
| Operating profit | $11.2M | +916% | +199% |
| Net earnings | $17.0M | — | +411% |
| Operating cash flow | $3.9M | — | +87% |
| Free cash flow | $3.2M | — | +87% |
What changed
Revenue was $32.0M in Q4 FY25, up 78% year over year and up 123% from the previous quarter. Manufacturing was the largest line at 99% of revenue.
Gross margin was 54.1%, up 8.8 points from a year earlier. Operating profit was $11.2M, a 34.9% margin (up 14.1 points year over year). Of the extra revenue versus a year earlier, 53% reached operating profit, above the 21% margin then. Operating expenses grew 40% against revenue growth of 78%. The fastest-growing cost line was Other operating costs (+377%). Net earnings were $17.0M, up 411% year over year. The effective tax rate was 11.8%. Non-operating items added $8.1M, 42% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $3.9M (up 87% year over year), 23% of net earnings. Non-cash charges added back $826K of depreciation and amortization and $52K of share-based compensation. Working capital and other items used $14.0M. Capital expenditures of $754K left free cash flow of $3.2M.
Questions
What was Elite Pharmaceuticals' revenue in the fourth quarter fiscal 2025?
Elite Pharmaceuticals (ELTP) reported revenue of $32.0M for the fourth quarter fiscal 2025 (Q4 FY25), +78% from a year earlier and +123% from the quarter before.
Was Elite Pharmaceuticals profitable in the fourth quarter fiscal 2025?
Operating profit was $11.2M (34.9% of revenue) and net earnings $17.0M.